Incyte | INCY - Current Assets


Incyte reported $6.03B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Agenus USD 78.81M 16.47M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Exelixis USD 1.25B 42.18M Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Moderna USD 5.82B 45M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026